AxoGen, Inc. (AXGN)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, AxoGen, Inc. currently loses $2.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
AxoGen, Inc. topped consensus in the second fiscal quarter of 2026, reporting revenue of $69.7 million against a $67.1 million estimate, +3.9%, when it reported results on July 29, 2026. Revenue rose 23.1% from $56.7 million a year ago, with the U.S. market carrying nearly all of the quarter at about $69.0 million. Gross profit came to about $50.7 million, with gross margin near 73%, while operating margin was about -3% as operating income came in at about -$2.2 million. Adjusted EPS was $0.12, up 0.0% from a year ago, and the company posted a net loss of about $1.5 million versus net income of about $579,000 a year ago. Operating cash flow was about $1.5 million. Consensus for the next period calls for EPS of $0.14 on revenue of $73.2 million.
Next report — what to expect
AxoGen, Inc. (AXGN) reports on November 4, 2026. Wall Street is looking for EPS of $0.13 on revenue of $73.2 million. For trailing context, revenue rose +23.1% year over year last quarter. AXGN has beaten EPS in 4 of its 8 most recent quarters.
About AxoGen, Inc.
AxoGen, Inc. develops and sells healthcare products for repairing injured or severed peripheral nerves and trades on the NASDAQ under AXGN. In FY2025, the company generated $225.2 million in revenue from a portfolio of surgical nerve repair and soft-tissue products used by clinicians in reconstructive procedures.
Today's Snapshot
AXGN closed 3.8% higher on heavier trading than usual. Barclays analysts cut their expected AxoGen share price to $50 from $55. AXGN reports earnings on 28 October.
Trading Volume
Above 10d avg 1.3M
2.1M
vs S&P 500 Today
Strong Outperformance
+4.28%
Updated: October 23, 2026 at 20:08 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$36.69 - $41.31Sell
- RSI (14)46.42Neutral
- Stochastic %K (14, 3, 3)65.39Neutral
- MACD Level (12, 26)-1.85Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.